Introduction: The effect of exenatide in weight
INTRODUCTION
Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. The World Health Organization (WHO) estimates that at least 2.8 million adults die each year as a result of being overweight or obese and that 44% of the diabetes burden, 23% of the ischemic heart disease burden, and 7-41% of the burden associated with certain cancers are attributable to overweight and obesity [1] .
Links between obesity and diabetes have been firmly established [2] [3] [4] . In obesity, visceral fat secretes adipocytokines such as tumor necrosis factor-a (TNF-a) [5] and resistin [6] , resulting in insulin resistance, which then progresses to impaired insulin secretion. Weight reduction can attenuate the abnormal adipocytokine secretion and may improve insulin resistance and glucose metabolism [7] . Therefore, weight loss can be used as a therapeutic treatment for patients with obesity-induced diabetes; however, if the desired weight loss is not achievable, medication for diabetes management is necessary in addition to weight management.
Gut peptides, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are secreted in a nutrient-dependent manner and stimulate glucose-dependent insulin secretion [8, 9] .
Exenatide, a GLP-1 analog, is a new class of antidiabetic drug that potentiates glucosedependent insulin secretion, lowers serum glucagon levels, slows gastric emptying, and may promote weight loss by increasing satiety [10] [11] [12] [13] . The effect of exenatide in weight loss has been reported, with considerable variation in the amount of weight that is lost [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] .
This case report presents a case of a morbidly obese patient with type 2 diabetes using exenatide who successfully lost 37.5 kg of body weight in a year and experienced improved glycemic control. To assess the efficacy of this drug, we also report hormonal changes in insulin, glucagon, GLP-1, and GIP levels before and after the exenatide treatment.
CASE REPORT

History of Obesity and Diabetes
A 59-year-old Japanese woman began experiencing weight gain at the age of 38 years due to overeating in response to mental stress. 
Administration of Exenatide
Following the patient's weight reduction in For all occasions, total caloric intake was maintained at 1,600 kcal per day (breakfast 365-410 kcal). To assess the minimum amount of energy required by the patient, her resting metabolic rate (RMR) was measured using a FitMate metabolic system (Cosmed, Rome, Italy). were done [24, 25] . In addition, the quantitative insulin-sensitivity check index (QUICKI) was calculated using the standard formula: 1/[log (glucose) ? log (insulin)] [26] . (Fig. 2b) . The active GLP-1 and total GIP levels decreased at all of the measurement points in August 2013 compared to those in August 2012 (Fig. 2c, d ).
DISCUSSION
Although substantial lifestyle changes, such as an increase in physical activity and dietary modifications, are essential and effective for obesity management; low compliance results in a need for pharmacological or surgical intervention in some cases. For the patient in this report, dietary modifications, exercise, and a pharmacological intervention were not effective, and surgical intervention was not an option. However, the use of exenatide contributed to a 37.5 kg weight loss and improved glycemic control in the patient. This improvement in glycemic control was related to both the weight loss and exenatide therapy; The fluctuations in the post-prandial insulin levels displayed in the patient were related to the changes in her weight; when her weight was higher (133.8 kg), the insulin levels increased, and when her weight was lower (112.1 and 96.3 kg), the insulin levels decreased. This relationship indicated that the level of insulin resistance decreased, and the hyperinsulinemia was ameliorated.
Glucagon levels decreased after 1 year of exenatide therapy, despite the decrease in glucose levels. Although GLP-1 is a powerful suppressor of glucagon secretion, a decrease in glucose levels should result in increased glucagon secretion. The balance of these phenomena may lead to a decrease in glucagon secretion. Secretion of GLP-1 is generally impaired in obesity [27] resulting in a reduction in the circulating GLP-1 levels in obese patients [10, 28, 29] . Moreover, the GLP-1 response to oral stimulation has been negatively correlated with BMI [27, 29] , and weight loss is associated with an increased GLP-1 response to meal ingestion [28] . However, in this case report, the patient's GLP-1 levels were reduced at all of the post-prandial measurements following the exenatide treatment. This may be due to the decreased glucose levels because GLP-1 is secreted in a glucose-dependent manner. In addition, the effect of exenatide on gastric emptying or the inhibitory feedback for GLP-1 secretion may explain the reduction in GLP-1 levels [14, 30] . The post-prandial total GIP levels were also decreased in the patient following exenatide therapy. The potential reason for this is unclear, but it might be attributed to the reduction in glucose levels.
Measurements of active GIP in future studies may provide more insight into this relationship.
Islet b cell failure in type 2 diabetes occurs when the islets are unable to sustain b cell compensation in the presence of insulin resistance. Weight loss often improves islet b cell function in association with reductions in insulin resistance [31, 32] . However, the islet b cell failure may be progressive and, therefore, not recoverable, particularly after hyperglycemia is established, which leads to poorly functioning, de-differentiated b cells, and a loss of b cell mass from apoptosis [33] . Preclinical studies provide strong evidence that exenatide plays an important role in the maintenance of b cell mass and function by increasing the expression of key b cell genes, stimulating islet cell proliferation and neogenesis, and inhibiting islet cell apoptosis [13] . However, human b cells appear to be much less responsive to proliferative agents such as GLP-1 compared to rodent b cells [34] , and b cell replication is substantially diminished in older human subjects [35] . This may explain the changes observed in the HOMA-b values in the patient, which indicated that the ability to secrete insulin was not [36] , leptin [37] [38] [39] [40] , resistin [6] , and ghrelin [41] are the hormones that modulate appetite and affect food intake. The levels of these hormones were not measured; however, they may contribute to understanding the extreme weight loss by exenatide in the patient.
A previous study [42] demonstrated that 1 year of exenatide treatment significantly improved b cell function and decreased body weight in the presence of similar improvements in glycemic control, when compared with insulin glargine treatment. However, after cessation of the exenatide therapy, these beneficial effects were not sustained,
suggesting that ongoing treatment is necessary for exenatide to be effective. Similarly, in the present study, the patient's appetite recovered after ceasing exenatide treatment, and she regained 3 kg within the following 2 months.
The treatment with another type of GLP-1 receptor agonist, liraglutide, led to weight loss in overweight or obese patients with or without type 2 diabetes [43] [44] [45] [46] [47] . In addition, the current phase 3, randomized, controlled trial demonstrates the efficacy of liraglutide 3.0 mg per day, combined with lifestyle modification, in facilitating the maintenance of clinically meaningful weight loss; thus, liraglutide holds promise as an anti-obesity drug [48] . Moreover, a once-weekly formulation of exenatide was developed recently, and patients treated with once-weekly exenatide showed better glycemic control with sustained overall weight loss than patients treated with insulin glargine [49, 50] .
Therefore, these drugs can be an alternative option for patients such as the one described in this case report.
In conclusion, 1 year of exenatide treatment was effective for reducing body weight and improving glycemic control in a 59-year-old morbidly obese woman with type 2 diabetes. At the same time, her insulin sensitivity recovered but the ability to secrete insulin did not recover.
After 1 year of exenatide treatment, decreased glucagon, active GLP-1, and total GIP levels were observed following a meal, suggesting that exenatide might affect these hormonal reactions.
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